Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics Tobira Therapeutics Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

Tobira Therapeutics
Tobira Therapeutics If you want to receive important updates and event information from Tobira, click here.
Tobira Therapeutics
 

TOBIRA NEWS

3.26.14
Tobira Therapeutics Appoints Chairman Laurent Fischer, MD, Chief Executive Officer and Christopher Peetz Chief Financial Officer

11.4.13
Tobira Therapeutics Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013

10.17.13
Tobira Therapeutics Presents Positive 48-Week Data from Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection at the 14th European AIDS...

Tobira Therapeutics
Tobira Therapeutics
  Digital Endeavor Websites